Search
for
Sort by
Research 61–90 of 1000+
- Biological therapy in the treatment of melanoma
- The JAK/STAT signaling pathway: from bench to clinic
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Management of Toxicities of Targeted Therapies
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
- Basal Cell Carcinoma, Hedgehog Signaling, and Targeted Therapeutics: The Long and Winding Road
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- The role of protein lactylation in skin diseases: from molecular mechanisms to potential therapeutics
- Role of janus kinase inhibitors in the treatment of alopecia areata
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Metabolic pathways of eicosanoids—derivatives of arachidonic acid and their significance in skin
- Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Hair Re-Pigmentation After Nilotinib
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Integrated single-cell chromatin and transcriptomic analyses of peripheral immune cells in patients with alopecia areata
- A review of Janus kinase inhibitor use in scarring alopecia
- Mathematical Modeling and Inference of Epidermal Growth Factor-Induced Mitogen-Activated Protein Kinase Cell Signaling Pathways
- Grand challenges in dermatologic drug discovery: four priorities to transform skin disease treatment